<div id="readability-page-1"><p>In a report released on March 30,  from UBS maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H, with a price target of <span id="expert-recommendation-target">HK$32.90</span>. The company’s shares closed last Monday at HK$18.27.</p><h3>End of Quarter Sale - 50% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul>  <p>Pharmaron Beijing Co., Ltd. Class H has an analyst consensus of Moderate Buy, with a price target consensus of €3.64.</p></div>

159316

03759

516500

<p>UBS has maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$32.90. The shares closed at HK$18.27 last Monday. The analyst consensus for the company is a Moderate Buy, with a price target consensus of €3.64.</p>

Tip Ranks

E Fund Hang Seng SCHK Innovative Drug ETF

PHARMARON

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

Guotai CSI Bio-medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Pharmaron Beijing Co., Ltd. Class H (17Q1) Gets a Buy from UBS